Home » Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront

Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront

August 14, 2012

Pfizer has agreed to acquire rights to market AstraZeneca’s popular heartburn drug Nexium for OTC use, paying $250 million up front as well as milestone and royalty payments.
The Wall Street Journal

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

MiRXES Earns CE Mark for COVID-19/Flu Test

Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements